REMIFENTANIL FOR INJECTION POWDER FOR SOLUTION

Maa: Kanada

Kieli: englanti

Lähde: Health Canada

Aktiivinen ainesosa:

REMIFENTANIL (REMIFENTANIL HYDROCHLORIDE)

Saatavilla:

TEVA CANADA LIMITED

ATC-koodi:

N01AH06

INN (Kansainvälinen yleisnimi):

REMIFENTANIL

Annos:

1MG

Lääkemuoto:

POWDER FOR SOLUTION

Koostumus:

REMIFENTANIL (REMIFENTANIL HYDROCHLORIDE) 1MG

Antoreitti:

INTRAVENOUS

Kpl paketissa:

1ML

Prescription tyyppi:

Narcotic (CDSA I)

Terapeuttinen alue:

OPIATE AGONISTS

Tuoteyhteenveto:

Active ingredient group (AIG) number: 0133098001; AHFS:

Valtuutuksen tilan:

CANCELLED POST MARKET

Valtuutus päivämäärä:

2021-07-30

Valmisteyhteenveto

_ _
_ _
_Page 1 of 42_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
N
REMIFENTANIL FOR INJECTION
1 mg/vial, 2 mg/vial of remifentanil
Lyophilized Powder for Injection
Sterile
Opioid Component to Anesthesia
Teva Canada Limited
Date of Revision:
30 Novopharm Court
January 2, 2019
Toronto, Ontario
M1B 2K9
Control Number: 221336
_ _
_ _
_Page 2 of 42_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................... 3
SUMMARY PRODUCT INFORMATION
...................................................................................
3
INDICATIONS AND CLINICAL USE
.........................................................................................
3
CONTRAINDICATIONS
..............................................................................................................
3
WARNINGS AND PRECAUTIONS
.............................................................................................
4
ADVERSE REACTIONS
.............................................................................................................
14
DRUG INTERACTIONS
.............................................................................................................
16
DOSAGE AND ADMINISTRATION
.........................................................................................
17
OVERDOSAGE
...........................................................................................................................
23
ACTION AND CLINICAL PHARMACOLOGY
.......................................................................
24
STORAGE AND STABILITY
.....................................................................................................
28
DOSAGE FORMS, COMPOSITION AND PACKAGING
........................................................ 28
PART II: SCIENTIFIC INFORMATION
...............................................................................
29
PHARMACEUTICAL INFORMATION
...................................................................................